Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of “Moderate Buy” by Brokerages

Merck & Co., Inc. (NYSE:MRK) has been given a consensus recommendation of “Moderate Buy” by the twenty-five brokerages that are presently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $151.3182.

Several analysts recently issued reports on MRK shares. Guggenheim increased their price target on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Scotiabank boosted their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Bank of America raised their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, HSBC boosted their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday.

Merck & Co., Inc. Stock Performance

MRK opened at $144.68 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $156.92. The firm has a market cap of $356.96 billion, a P/E ratio of 115.75, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. The business’s fifty day moving average is $136.22 and its 200-day moving average is $124.26.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts raised price targets: HSBC lifted its target from $150 to $172 and maintained a “buy” rating, while Guggenheim raised its target to $170. Leerink Partners also increased its target from $127 to $161 and assigned an “outperform” rating. These revisions indicate continued confidence in Merck’s earnings potential and pipeline. Guggenheim Increases Merck Price Target
• Positive Sentiment: Pipeline strategy may help address Keytruda risks: Merck is pairing antibody-drug conjugates with Keytruda in women’s cancer treatments, an effort to expand its oncology franchise and offset the eventual impact of Keytruda’s patent cliff. Merck Pairs ADCs With Keytruda
• Neutral Sentiment: Investors are reassessing Merck’s valuation: A comparison with Eli Lilly highlights that Merck is trading at a higher valuation despite its slower expected growth, prompting questions about whether its pipeline, cash generation and defensive characteristics justify the premium. Merck Stock Versus Eli Lilly
• Neutral Sentiment: Market attention remains elevated: Merck was among the stocks most watched by Zacks users, suggesting strong investor interest but not necessarily a change in fundamentals. Merck Investor Attention
• Negative Sentiment: Shares declined with the broader market and underperformed during the session: The trading update provided no new company-specific catalyst, leaving valuation concerns and the Keytruda patent-cliff debate as the primary pressures on the stock.

Insider Activity

In other news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president directly owned 110,167 shares in the company, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System raised its holdings in Merck & Co., Inc. by 12,537.4% in the 2nd quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock valued at $62,286,552,000 after buying an additional 480,884,635 shares during the last quarter. BlackRock Inc. grew its holdings in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares during the last quarter. State Street Corp increased its position in Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after acquiring an additional 1,859,990 shares during the period. Wellington Management Group LLP increased its position in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.